Christopher O’Connell is a highly regarded senior executive, board member and advisor, with more than three decades of leadership experience across the medical devices, life sciences and global healthcare industries. He built his career over two decades at Medtronic, serving in multiple business areas and functions during an era of rapid expansion, most recently as President of its Restorative Therapies Group. He was also a member of the Medtronic Executive Committee for nine years.

Christopher O’Connell then became CEO and President of Waters Corporation, which he led to robust business and share price growth for over five years. He currently serves as an Independent Director of innovative growth companies in medical devices, life sciences and diagnostics, as well as several non-profit organizations.

The appointment of Christopher O’Connell comes at a pivotal time as A3P focuses on expanding its pioneering Stockholm3 test for screening and early prostate cancer detection to the United States.

“We are thrilled to welcome Chris to the A3P Board. His deep knowledge of the U.S. healthcare ecosystem and proven track record in building world-class diagnostics and MedTech businesses will be instrumental as we scale our operations with the aim of making Stockholm3 the new global standard of care for prostate cancer screening”, said Martin Steinberg, Executive Chairman.

“Stockholm3 has the potential to transform how prostate cancer is screened and managed in the United States. It’s novel combination of advanced biomarkers and genetics into a single blood test, as well as its proven effectiveness in over 90,000 men studied, creates a unique opportunity to create a new standard of care for prostate cancer screening - detecting more aggressive cancers earlier while reducing unnecessary procedures. I’m excited to join A3P’s mission to bring this important innovation to men across the U.S. and around the world,” said Christopher O’Connell.